Pulmostem is under clinical development by Amniotics and currently in Phase II for Influenzavirus A Infections. According to GlobalData, Phase II drugs for Influenzavirus A Infections have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pulmostem’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pulmostem overview

Pulmostem is under development of the treatment of acute respiratory distress syndrome, coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), idiopathic pulmonary fibrosis, lung transplantation, Influenza A and respiratory syncytial virus infections. It is administered through intravenous route. The therapeutic candidate comprises of allogeneic, mesenchymal stem cells derived from amniotic fluid.

Amniotics overview

Amniotics is a biopharmaceutical company that includes in mesenchymal stem cells (MSC). The company discovers and develops novel stem cell-based. Amniotics developed sort cells for treatment of pulmonary indications, CNS indications, kidney-specific indications and dermatological indications. The company is investigating its lead drug candidate, PulmoStem. It also investigating CogniStem against spinal muscular atrophy in children; CutiStem therapy for epidermolysis bullosa, burns and wound healing; and NephroStem to treat acute kidney injury, and C3 glomerulopathy. Amniotics operates a GMP-approved manufacturing facility to produce advanced therapy medicinal products (ATMPs). It collaborates with Universities, hospitals and the biopharmaceutical industry. Amniotics is headquartered in Lund, Sweden.

For a complete picture of Pulmostem’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.